Humana (HUM) Stock Forecast & Price Target

Humana's positive outlook is supported by significant improvements in operational margins and revenue streams, particularly within its Group Medicare Advantage segment, which saw a 500 basis point margin enhancement through strategic re-contracting. The company's commitment to expanding its Specialty, Direct-to-Consumer, Direct-to-Employer, and Home Delivery services is projected to bolster earnings, while its CenterWell division benefits from a 16% revenue growth driven by strong pharmacy performance. Additionally, Humana's effective management strategies and continued focus on improving productivity in its Home Health operations are expected to further mitigate reimbursement pressures and enhance overall financial performance.

Humana faces significant downside risks due to increased competition in the Medicare Advantage (MA) market, inadequate reimbursement rates, and declining membership in its Prescription Drug Plan (PDP) offerings. The company’s 2026 and 2027 adjusted EPS estimates have been lowered amid expectations of margin pressures and a substantial headwind from MA Star ratings, estimated at around $3.5 billion year-over-year, which is projected to significantly impact earnings. Additionally, ongoing challenges in healthcare service growth and net investment income pressures further contribute to a cautious outlook on Humana’s financial performance.